Europe — EMA
Ezetimibe/Simvastatine Viatris (Simvastatin, Ezetimibe)
Ezetimibe/Simvastatin Viatris combines two active ingredients to help manage cholesterol levels. This oral medication is designed to support cardiovascular heal
Request sourcing
What is Simvastatin, Ezetimibe?
Ezetimibe/Simvastatin Viatris combines two active ingredients to help manage cholesterol levels. This oral medication is designed to support cardiovascular health by reducing LDL cholesterol and improving lipid profiles.
What is Simvastatin, Ezetimibe used for?
Ezetimibe/Simvastatin Viatris is commonly used to lower LDL cholesterol and triglycerides, which are types of fat in the blood. This medication is often prescribed for individuals with high cholesterol levels who need to manage their lipid profiles. It works by inhibiting the absorption of cholesterol in the intestines and increasing the liver's ability to remove cholesterol from the bloodstream.
What are the side effects of Simvastatin, Ezetimibe?
Common effects of Ezetimibe/Simvastatin Viatris may include headaches, muscle pain, and digestive issues. Some users might experience dizziness or fatigue. These effects vary among individuals and are not experienced by everyone who takes the medication.
What precautions apply to Simvastatin, Ezetimibe?
It is important to follow the prescribed dosage and administration instructions for Ezetimibe/Simvastatin Viatris. This medication should be used under the supervision of a healthcare provider. Individuals with liver disease or a history of muscle disorders should discuss their medical history with their healthcare provider before starting this medication.
What does Simvastatin, Ezetimibe interact with?
Ezetimibe/Simvastatin Viatris may interact with certain medications, including other cholesterol-lowering drugs, antibiotics, and antifungal medications. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be moderated while using this medication.



